330 related articles for article (PubMed ID: 27922234)
1. Long term azithromycin therapy in patients with cystic fibrosis.
Emiralioğlu N; Öztürk Z; Yalçın E; Doğru D; Özçelik U; Kiper N
Turk J Pediatr; 2016; 58(1):34-40. PubMed ID: 27922234
[TBL] [Abstract][Full Text] [Related]
2. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.
Wolter J; Seeney S; Bell S; Bowler S; Masel P; McCormack J
Thorax; 2002 Mar; 57(3):212-6. PubMed ID: 11867823
[TBL] [Abstract][Full Text] [Related]
3. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of azithromycin in patients with cystic fibrosis.
Samson C; Tamalet A; Thien HV; Taytard J; Perisson C; Nathan N; Clement A; Boelle PY; Corvol H
Respir Med; 2016 Aug; 117():1-6. PubMed ID: 27492507
[TBL] [Abstract][Full Text] [Related]
5. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
Walicka-Serzysko K; Sands D
Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
[TBL] [Abstract][Full Text] [Related]
6. [Azithromycin therapy in cystic fibrosis].
Máiz Carro L; Cantón Moreno R
Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744
[TBL] [Abstract][Full Text] [Related]
7. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
8. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
9. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
10. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
[TBL] [Abstract][Full Text] [Related]
11. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
Wilms EB; Touw DJ; Heijerman HG
Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
[TBL] [Abstract][Full Text] [Related]
13. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
14. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.
Phaff SJ; Tiddens HA; Verbrugh HA; Ott A
J Antimicrob Chemother; 2006 Apr; 57(4):741-6. PubMed ID: 16469851
[TBL] [Abstract][Full Text] [Related]
15. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
16. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
[TBL] [Abstract][Full Text] [Related]
17. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.
Saiman L; Mayer-Hamblett N; Anstead M; Lands LC; Kloster M; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
Pediatr Pulmonol; 2012 Jul; 47(7):641-8. PubMed ID: 22684984
[TBL] [Abstract][Full Text] [Related]
18. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
19. Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis.
Tarique AA; Tuladhar N; Kelk D; Begum N; Lucas RM; Luo L; Stow JL; Wainwright CE; Bell SC; Sly PD; Fantino E
Cells; 2024 Jan; 13(2):. PubMed ID: 38247856
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
